A
Atea Pharmaceuticals, Inc. (AVIR)
NMS – Real Time Price. Currency in USD
5.50
+0.09 (1.66%)
At close: May 12, 2026, 4:00 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NMS – Real Time Price. Currency in USD
5.50
+0.09 (1.66%)
At close: May 12, 2026, 4:00 PM EDT
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). The company also developing AT-587, that is in Phase 1 clinical trial for the treatment of chronic HEV infection. In addition, it offers a proprietary platform of nucleosides and nucleotides for virology, medicinal chemistry, and antiviral drug development. The company has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of ruzasvir. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.
| Name | Position |
|---|---|
| Dr. Janet M. J. Hammond M.D., Ph.D. | Chief Development Officer |
| Dr. Jean-Pierre Sommadossi Ph.D. | Founder, Chairman, CEO & President |
| Dr. Maria Arantxa Horga M.D. | Chief Medical Officer |
| Mr. Adel Moussa Ph.D. | Executive Vice President of Chemistry |
| Mr. John F. Vavricka | Chief Commercial Officer |
| Mr. Keith Pietropaolo | Executive VP of Clinical Sciences & Project Management |
| Mr. Wayne Foster CPA | Executive VP of Finance & Chief Accounting Officer |
| Mr. Xiao-Jian Zhou Ph.D. | Executive Vice President of Early Stage Development |
| Ms. Andrea J. Corcoran J.D. | CFO, Executive VP of Legal & Secretary |
| Ms. Jonae R. Barnes | Senior Vice President of Investor Relations & Corporate Communications |
| Date | Type | Document |
|---|---|---|
| 2026-04-27 | DEFA14A | avir-defa_14a-2026.htm |
| 2026-04-27 | DEF 14A | avir-20260427.htm |
| 2026-03-05 | 10-K | avir-20251231.htm |
| 2026-01-08 | 8-K | d800383d8k.htm |
| 2025-11-12 | 10-Q | avir-20250930.htm |
| 2025-08-07 | 10-Q | avir-20250630.htm |
| 2025-06-20 | 8-K | d936449d8k.htm |
| 2025-05-12 | 8-K | d923851d8k.htm |
| 2025-04-29 | DEF 14A | d931077ddef14a.htm |
| 2025-04-17 | 8-K | d915073d8k.htm |